Skip to main content

Replication: Crisis at Bay

Image result for psych labs Wundt

There has been much talk of late about a "replication crisis" in psychology. Important experimental results, sometimes results that have generated considerable bodies of literature, peer-reviewed and otherwise, have turned out to have been resting on sand when subjected to rigorous efforts at replication. One notorious example involves the "power pose" (standing, feet apart, hands on hips, chin up). Striking the power pose was supposedly proven to have a range of valuable psychological effects, including the reduction of stress. Except that it doesn't. The effect was the consequence of data mining and statistical noise.

Such failed replication efforts have reopened talk about whether psychology deserves the title "science" at all.

Fortunately, for those of us who will to believe that there IS such a science, some important results have survived efforts at replication. This is especially so it appears in the study of cognition, a very Jamesian branch of psychology.

Nine findings in particular have been found to stand on a much sounder-than-sand empirical foundation. (There's a link to a list.)

The most fascinating of these, to me, involves "motor priming" and subliminal perception (third on the list). But I'll let you decided of the respective degree of fascination for yourself dear reader.

In the event you're wondering: I have illustrated this post with the visage of William Wundt, one of the pioneers of experimental psychology.

Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…